Genmab — Februar 2019

[hda]

Samme koncern - samme artikel

[hda]

Baggrunden for bekymringen skal findes i et nyt studie, der er blevet startet af en række på Saint Antoine Hospital i Frankrig

[hda]

Fundet på Jyllandspostens hjemmeside. Kan kun læse de første 7-8 linjer ..

[peter12]

Det var det studie der blev nævnt her for en lille uge siden. Vi skal vente 4 år på resultatet https://clinicaltrials.gov/ct2/show/NCT03836014?term=daratumumab&draw=2

[E_L]

ok, that must be that new trial Mohty started

[E_L]

that is not news to us

[E_L]

it is to the market apparently.

[Bulder]

Det får minimal betydning. Det er for det første 2. linje og så går det ud på at finde ud af om man kan stoppe behandlingen efter 24 mdr. eller om den skal fortsætte indtil relaps. Men ingen kender endnu svaret.

[Bulder]

301 Moved Permanently

(www.clinicaltrials.gov)

[E_L]

and it will take 6 years for the study to complete

[Plimsoller]

Not 4 years E L?

[Bulder]

If they start recruiting coming March, they'll have the first OS-data in 4 years. But that will not be enough to conclude. They'll have to wait for a significant result. Closer to 6 years.

[Solsen]

Not news and I belive no significant influence on the sales. Far far out in future.

[Solsen]

And after 6 years it will take another two years to make any difference on new start ups.

[Solsen]

Now we are two days from where we will se if shorters can hold Genmab from breaking up.

[hda]

Hopefully you are right Solsen

[nohope]

Well, I don´t know who to blame but today wasn´t too good - unless you are short.

[Tandfeen-2]

Håber hver gang jeg checker mails at der er besked fra Genmab om godkendt 1. Linje USA. Er jeg den eneste?

[Solsen]

Hvilken behandling er egentlig på labelen i 2. line. Er det annoncerede forsøg egentlig en begrænsning eller udvidelse. Tror ikke analytikerne medregner megen maintenance i darasalget.

[E_L]

I actually think there is a bigger chance for combination therapy to scale down to only daratumumab after a certain time, very well tolerated and much cheaper as the combo. Time will tell.